Quetiapine versus other atypical antipsychotics for schizophrenia

Keyphrases

• Schizophrenia 100%
• Quetiapine 100%
• Atypical Antipsychotics 100%
• Randomized Controlled Trial 83%
• Confidence Interval 83%
• Risk Ratio 44%
• Weight Gain 38%
• Risperidone 27%
• Olanzapine 27%
• Ziprasidone 27%
• Antiparkinsonian Drugs 22%
• Paliperidone 22%
• Prolactin 16%
• Aripiprazole 16%
• People with Schizophrenia 16%
• Schizophrenia Spectrum Disorders 11%
• Movement Disorders 11%
• Cholesterol 11%
• Adverse Effects 11%
• Efficacy Data 11%
• Random Effects Model 11%
• Clinical Meaning 11%
• Parkinsonian 11%
• Clozapine 11%
• Mental States 5%
• Continuous Data 5%
• Selection Criteria 5%
• Search Methods 5%
• Intention-to-treat 5%
• Cochrane 5%
• Limited Value 5%
• Drug Treatment 5%
• Calculated Risk 5%
• Beneficial Outcomes 5%
• Pharmaceutical Companies 5%
• Drug Approval 5%
• Gain Profile 5%
• QT Prolongation 5%
• First-line Drugs 5%
• Number-needed-to-treat 5%
• Total Body Weight 5%
• Extrapyramidal Symptoms 5%
• Negative Syndrome 5%
• Second-generation Antipsychotics 5%
• Amisulpride 5%
• Sertindole 5%
• Zotepine 5%
• State Differences 5%
• Oral Form 5%
• Extracted Data 5%
• Dichotomous Data 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Atypical Antipsychotics 100%
• Quetiapine 100%
• Randomized Controlled Trial 83%
• Risperidone 27%
• Olanzapine 27%
• Ziprasidone 27%
• Paliperidone 22%
• Antiparkinson Agent 22%
• Aripiprazole 16%
• Prolactin 16%
• Random Effects Model 11%
• Motor Dysfunction 11%
• Clozapine 11%
• Pharmacotherapy 5%
• Group Trial 5%
• Number Needed to Treat 5%
• Drug Approval 5%
• Zotepine 5%
• Sertindole 5%
• Side Effect 5%
• Negative Syndrome 5%
• Amisulpride 5%
• Positive Syndrome 5%
• Antipsychotic Drug 5%